Cooper Pharma has entered into a strategic partnership with China’s Jemincare Pharmaceutical Group, marking a significant milestone for Morocco’s pharmaceutical industry. This new alliance, announced on Friday, brings together the Casablanca-based company and one of China’s major pharmaceutical players with a shared goal: to drive innovation in medical treatments while boosting Morocco’s industrial self-reliance in the health sector.
The agreement sets the stage for joint research and development efforts focused on high-value therapeutic solutions. It also aims to establish new manufacturing capabilities within Morocco, relying on state-of-the-art infrastructure and production processes aligned with global standards. This initiative reflects a broader vision to elevate Morocco’s role in the pharmaceutical value chain and reduce reliance on imported medicines.
A central component of the deal is the transfer of technology. The two companies intend to equip Moroccan teams with advanced expertise, fostering a long-term upgrade in the country’s pharmaceutical ecosystem. By building local skills and knowledge, the partnership hopes to create a more resilient and competitive industry. In the long run, this collaboration could significantly improve access to essential medicines across the region, while positioning Morocco as a key pharmaceutical hub in North and West Africa.
